Russell Investments Group Ltd. grew its stake in shares of Intersect ENT Inc (NASDAQ:XENT) by 18.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 49,408 shares of the medical equipment provider’s stock after buying an additional 7,589 shares during the period. Russell Investments Group Ltd. owned 0.16% of Intersect ENT worth $1,421,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the company. Alps Advisors Inc. raised its stake in Intersect ENT by 23.2% during the 3rd quarter. Alps Advisors Inc. now owns 53,893 shares of the medical equipment provider’s stock valued at $1,549,000 after purchasing an additional 10,160 shares during the period. Bellevue Group AG raised its stake in Intersect ENT by 129.1% during the 2nd quarter. Bellevue Group AG now owns 88,028 shares of the medical equipment provider’s stock valued at $3,297,000 after purchasing an additional 49,598 shares during the period. Bank of Montreal Can raised its stake in Intersect ENT by 947.0% during the 2nd quarter. Bank of Montreal Can now owns 44,981 shares of the medical equipment provider’s stock valued at $1,685,000 after purchasing an additional 40,685 shares during the period. Waddell & Reed Financial Inc. raised its stake in Intersect ENT by 1.6% during the 2nd quarter. Waddell & Reed Financial Inc. now owns 169,500 shares of the medical equipment provider’s stock valued at $6,348,000 after purchasing an additional 2,600 shares during the period. Finally, Segall Bryant & Hamill LLC bought a new stake in Intersect ENT during the 2nd quarter valued at approximately $693,000. 91.66% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:XENT opened at $30.76 on Friday. Intersect ENT Inc has a 1 year low of $25.15 and a 1 year high of $42.95.
Intersect ENT (NASDAQ:XENT) last released its quarterly earnings data on Monday, November 5th. The medical equipment provider reported ($0.25) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.02. Intersect ENT had a negative return on equity of 17.62% and a negative net margin of 20.00%. The business had revenue of $24.70 million for the quarter, compared to the consensus estimate of $24.09 million. During the same quarter in the previous year, the company posted ($0.15) EPS. The company’s revenue was up 10.8% compared to the same quarter last year. On average, sell-side analysts predict that Intersect ENT Inc will post -0.73 EPS for the current year.
In other Intersect ENT news, CFO Jeryl L. Hilleman sold 12,833 shares of Intersect ENT stock in a transaction that occurred on Monday, October 8th. The stock was sold at an average price of $27.99, for a total value of $359,195.67. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Lisa D. Earnhardt sold 20,000 shares of Intersect ENT stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $29.14, for a total value of $582,800.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 85,666 shares of company stock worth $2,505,926. Corporate insiders own 5.90% of the company’s stock.
Several analysts recently issued reports on XENT shares. Zacks Investment Research raised Intersect ENT from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research note on Wednesday, November 7th. ValuEngine raised Intersect ENT from a “hold” rating to a “buy” rating in a research note on Tuesday, October 2nd. Northland Securities reissued a “hold” rating and set a $28.00 target price on shares of Intersect ENT in a research note on Wednesday, October 17th. Finally, BidaskClub raised Intersect ENT from a “sell” rating to a “hold” rating in a research note on Thursday, October 11th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Intersect ENT has a consensus rating of “Buy” and a consensus target price of $37.17.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/12/08/russell-investments-group-ltd-has-1-42-million-stake-in-intersect-ent-inc-xent.html.
Intersect ENT Company Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Read More: What is a Stop Order?
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.